| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-135 | |
| Phytochemical name or plant extracts | Cirsimaritin | |
| PMID | 28784292 | |
| Literature evidence | The present study demonstrated that Cirsium japonicum extract and its active component cirsimaritin is an excellent candidate as an alternative anti-breast cancer drug. | |
| IUPAC name | 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxychromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Flavonoid | |
| Source of phytochemicals or plant Extracts | Cirsium japonicum | |
| Geographical availability | China North-Central, China South-Central, China Southeast, Inner Mongolia, Japan, Korea, Qinghai, Taiwan, Vietnam | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | VEGF, AKT, ERK | |
| Gene or Protein evidence | Cirsimaritin inhibited angiogenesis by downregulation of VEGF, p-Akt and p-ERK in MDA-MB-231 cells, suggesting that cirsimaritin is potentially useful as an anti-metastatic agent. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | The ICF-1 extract and cirsimaritin reduced tube formation by 12.69% at level of 25μg/ml and 32.18% at the levels of 6.25μM, respectively. | |
| Cell line/ mice model | MDA-MB-231 | |
| Additional information | The inhibition achieved was 36.89% at a level of 200μg/ml by the ICF-1 extract and 62.04% at a level of 100μM by cirsimaritin. | |
| PubChem ID | 188323 | |
| Additional PMIDs | 28784292 29457735 27938087 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:195527-1 | |
| Safety | NA |